# Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer

> **NCT01594918** · PHASE1 · COMPLETED · sponsor: **Rahul Aggarwal** · enrollment: 25 (actual)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** Cabazitaxel
- **DRUG:** Mitoxantrone
- **DRUG:** Prednisone
- **DRUG:** Pegfilgrastim

## Key facts

- **NCT ID:** NCT01594918
- **Lead sponsor:** Rahul Aggarwal
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2016-08
- **Final completion:** 2017-06-23
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2017-07-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01594918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01594918, "Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01594918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*